Shanghai Pharmaceuticals Holding

Diversified pharma

2607 · SSE · China

Public Market Listing

2607SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Pharmaceuticals Holding are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
CDK4 and CDK6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
ReninSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
SPH4336Phase 2/3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2026-12-01 · NCT05860465 · CT.gov ↗
What to watch
SPH4336Phase 1/2Advanced Solid Tumors
Est. primary completion 2026-12-31 · NCT05944224 · CT.gov ↗
What to watch
SPH4336Phase 2Breast Cancer Brain Metastases
Est. primary completion 2026-12-31 · NCT05872347 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$30.1B$212M$5.2B—report ↗

Shanghai Pharmaceuticals Holding reported revenue of $30,052.64M, up 2.7% YoY, R&D spend of $211.76M, down 6.1% YoY, and cash and equivalents of $5,160.04M for Q3 2025.

Figures only: this period's report disclosed no narrative text

View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$19.5B$132M$5.5B—report ↗
2025-Q1$9.7B$68M$5.0B—report ↗
2024-Q3$29.3B$226M$4.8B—report ↗
2024-H1$19.4B$154M——report ↗
2024-Q1$9.8B$70M$4.2B—report ↗
2023-Q3$27.3B$203M$4.0B—report ↗
2023-H1$19.2B$148M——report ↗
2023-Q1$9.7B$79M$3.9B—report ↗
2022-Q3$25.5B$203M$3.6B—report ↗
2022-H1$17.3B$125M$4.0B—report ↗
2022-Q1$9.0B$71M$5.8B—report ↗
2021-Q3$24.9B$211M$3.6B—report ↗
2021-H1$16.3B$136M$3.5B—report ↗
2021-Q1$8.0B$64M$3.4B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$41.9B$345M$4.8B—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$38.3B$333M——report ↗
2023-FY$36.8B$368M——report ↗
2022-FY$34.5B$314M——report ↗
2021-FY$33.5B$308M——report ↗